Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.89 USD | +1.43% | -1.59% | -11.42% |
Financials (USD)
Sales 2024 * | 461M | Sales 2025 * | 549M | Capitalization | 1.73B |
---|---|---|---|---|---|
Net income 2024 * | 137M | Net income 2025 * | 185M | EV / Sales 2024 * | 2.76 x |
Net cash position 2024 * | 461M | Net cash position 2025 * | 686M | EV / Sales 2025 * | 1.91 x |
P/E ratio 2024 * |
13
x | P/E ratio 2025 * |
9.82
x | Employees | 167 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.79% |
Latest transcript on Catalyst Pharmaceuticals, Inc.
1 day | -2.91% | ||
1 week | -4.30% | ||
Current month | -7.90% | ||
1 month | -7.44% | ||
3 months | +1.03% | ||
6 months | +13.36% | ||
Current year | -12.67% |
Managers | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 77 | 01-12-31 |
Richard Daly
CEO | Chief Executive Officer | 62 | 15-02-18 |
Michael Kalb
DFI | Director of Finance/CFO | 53 | Dec. 31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 77 | 01-12-31 |
Donald Denkhaus
BRD | Director/Board Member | 78 | 15-02-18 |
David Tierney
BRD | Director/Board Member | 60 | 02-09-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.05% | 29 M€ | -4.59% | ||
0.32% | 27 M€ | -5.44% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 14.89 | +1.43% | 772 195 |
24-04-25 | 14.68 | -2.91% | 926,397 |
24-04-24 | 15.12 | +2.65% | 942,143 |
24-04-23 | 14.73 | -2.45% | 992,474 |
24-04-22 | 15.1 | -0.20% | 1,015,778 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.67% | 1.73B | |
-4.74% | 87.53B | |
+2.63% | 40.42B | |
-21.76% | 29.48B | |
+58.56% | 25.43B | |
-14.78% | 15.59B | |
-18.49% | 11.49B | |
-15.61% | 11.1B | |
-44.02% | 11.3B | |
+5.17% | 8.75B |
- Stock Market
- Equities
- CPRX Stock